title: Serum matrix metalloproteinase-3 concentration is influenced by MMP-3 -1612 5A/6A promoter genotype and associated with myocardial infarction.
abstract: OBJECTIVE
  Matrix metalloproteinase-3 (MMP-3) is implicated in the formation of atherosclerotic plaques, and the MMP-3 -1612 5A/6A polymorphism is associated with myocardial infarction (MI) and stable coronary artery disease (CAD). The present study examined whether the -1612 5A/6A polymorphism in the promoter region of the MMP-3 gene influences serum concentrations of MMP-3 and whether serum concentrations of MMP-3 are related to extent of coronary atherosclerosis and risk of MI.
  
  
  METHODS
  This case-control study was conducted in three hospitals in the northern part of Stockholm. A total of 755 MI patients aged below 60 were screened, 433 entered and 387 completed the study. Three hundred and eighty-seven sex- and age-matched control subjects were recruited from the general population of the same county.
  
  
  METHODS
  The MMP-3 genotype was determined by Pyrosequencing(TM) and the serum MMP-3 concentration was quantified with an immunoassay. Severity and extension of CAD was assessed by quantitative coronary angiography in a subgroup of patients (n=243).
  
  
  RESULTS
  Patients had lower serum MMP-3 concentration than controls. There was a strong association between MMP-3 -1612 5A/6A genotype and serum concentrations of MMP-3. The presence of one or two copies of the 6A-allele was associated with a graded increase in serum MMP-3. In female patients there was an inverse correlation (r=-0.39, P<0.05) between serum MMP-3 concentration and plaque area. Conclusion. In conclusion, the serum concentration of MMP-3 is influenced by MMP-3 -1612 5A/6A genotype and associated with MI.
authors.affiliation: Atherosclerosis Research Unit, King Gustaf V Research Institute, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden. ann.samnegard@kids.ki.se
authors.forename: A
authors.initials: A
authors.lastname: Samnegård
authors.forename: A
authors.initials: A
authors.lastname: Silveira
authors.forename: P
authors.initials: P
authors.lastname: Lundman
authors.forename: S
authors.initials: S
authors.lastname: Boquist
authors.forename: J
authors.initials: J
authors.lastname: Odeberg
authors.forename: J
authors.initials: J
authors.lastname: Hulthe
authors.forename: W
authors.initials: W
authors.lastname: McPheat
authors.forename: P
authors.initials: P
authors.lastname: Tornvall
authors.forename: L
authors.initials: L
authors.lastname: Bergstrand
authors.forename: C-G
authors.initials: CG
authors.lastname: Ericsson
authors.forename: A
authors.initials: A
authors.lastname: Hamsten
authors.forename: P
authors.initials: P
authors.lastname: Eriksson
mesh_terms: D016022:Case-Control Studies; D017023:Coronary Angiography / Q000379:methods; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D019278:Matrix Metalloproteinase 3 / Q000097:blood* / Q000235:genetics; D008875:Middle Aged; D009203:Myocardial Infarction / Q000235:genetics*; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011401:Promoter Regions, Genetic / Q000235:genetics*; D012307:Risk Factors; D012720:Severity of Illness Index
chemical_list: D019278:Matrix Metalloproteinase 3